ArticleBMC psychiatry2014
Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy.
Article in BMC psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States.Advances in therapy · 2022Pooled it
- Antipsychotic Discontinuation and Re-initiation in Pregnant Women With Schizophrenia: A Retrospective Cohort Study From South Korea.Schizophrenia bulletin · 2026Article
- Lurasidone uses and dosages in Spain: RETROLUR, a real-world retrospective analysis using artificial intelligence.Frontiers in psychiatry · 2024Article
- Global Neuropsychopharmacological Prescription Trends in Adults with Schizophrenia, Clinical Correlates and Implications for Practice: A Scoping Review.Brain sciences · 2023Article
- Article
- Medication strategies in first episode psychosis patients: A survey among psychiatrists.Early intervention in psychiatry · 2022Article
- Liver enzymePharmacogenomics · 2020Article
- Atypical antipsychotic use during pregnancy and birth defect risk: National Birth Defects Prevention Study, 1997-2011.Schizophrenia research · 2020Article
- Comparison of Clinical Characteristics Between the Patients with Schizophrenia on Clozapine Treatment with Those Taking Combination of Long-Acting Injectable and Oral Antipsychotics.Noro psikiyatri arsivi · 2019Article
- Coprescription of QT interval-prolonging antipsychotics with potentially interacting medications in Thailand.Therapeutic advances in drug safety · 2019Article
- A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States.ClinicoEconomics and outcomes research : CEOR · 2018Review
- Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy.Clinical practice and epidemiology in mental health : CP & EMH · 2017Article
- Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States.Journal of clinical psychopharmacology · 2016Article
- Chemical Structure-Biological Activity Models for Pharmacophores' 3D-Interactions.International journal of molecular sciences · 2016Review
- Antipsychotic Medication Prescribing Practices Among Adult Patients Discharged From State Psychiatric Inpatient Hospitals.Journal of psychiatric practice · 2016Article
- Metabolic Syndrome in South African Patients with Severe Mental Illness: Prevalence and Associated Risk Factors.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objective of this study was to characterize real-world treatment patterns in the prescription of antipsychotic polypharmacy (≥ 2 concurrent antipsychotics) compared with antipsychotic monotherapy for patients with schizophrenia.
methodsThis study was a retrospective claims-based analysis of patients (aged 13-64 years) with schizophrenia belonging to an employer-based health plan. Duration of therapy was measured as the number of treatment days over one year following the initial date of antipsychotic therapy. Discontinuation was defined as a 90-day gap in antipsychotic treatment (or in at least one antipsychotic for the polypharmacy group). Logistic regression analyses were used to predict discontinuation within one year. Ordinary Least Squares (OLS) regressions were used to predict duration of therapy (by type of therapy) when controlling for gender, region, number of somatic and psychiatric comorbidities, Deyo-Charlson comorbidity score, and number of psychiatric and somatic medications.
resultsOf the 4,156 patients, 3,188 received monotherapy and 968 received polypharmacy. Mean age was 40 years (37.8 years for polypharmacy vs 40.3 years for monotherapy, p < 0.001). Within one year, 77% of the polypharmacy group and 54% of the monotherapy group discontinued treatment. The average duration of therapy was 163 [SD = 143] days in the polypharmacy group vs 253 [SD = 147] days in the monotherapy group. In both cohorts, patients <25 years had a higher frequency of discontinuations than those ≥ 26 years. Age and polypharmacy were independent predictors of treatment duration and discontinuation prior to one year.
conclusionsOne quarter of patients with schizophrenia received antipsychotic polypharmacy. Discontinuation was higher in the polypharmacy group. Age and polypharmacy were significant predictors of treatment discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.